Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
作者信息
Burgel Pierre-Régis
机构信息
Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France
Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France.
出版信息
Eur Respir J. 2024 Feb 29;63(2). doi: 10.1183/13993003.00233-2024. Print 2024 Feb.
PMID:38423591
Abstract
摘要
Zotero 插件